AUPH - Company ID 0001600620
Aurinia Pharmaceuticals Inc. trades as AUPH and has a market capitalization of $2.03 B, making it the #2119 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $283.06M, up 20.4% from the prior year and net income of $287.20M. This page tracks Aurinia Pharmaceuticals Inc. through 595 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 7 fiscal years Aurinia Pharmaceuticals Inc.'s revenue grew from $463.00K to $283.06M, a compound annual growth rate of 150.1%. Net profit margin expanded from -11464.1% to 101.5% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| SC TO-T/A | - | 2026-05-11 |
About Aurinia Management Team Board of Directors Responsibility
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right | Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Announces Management Transition | Aurinia Pharmaceuticals Inc. (AUPH)
About Aurinia Management Team Board of Directors Responsibility
About Aurinia Management Team Board of Directors Responsibility
The largest companies sharing Aurinia Pharmaceuticals Inc.'s SEC industry classification (pharmaceutical preparations).
Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of $2.03 B as of 2026-07-11, ranking #2119 among US-listed companies.
Aurinia Pharmaceuticals Inc. reported revenue of $283.06M for fiscal year 2025, an increase of 20.4% year over year.
Yes. Aurinia Pharmaceuticals Inc. reported net income of $287.20M in its latest fiscal year.